25 May 2013
Keywords: fda, cox-2, recommendations, benefit, bextra, celebex, recent
Article | 04 April 2005
The recent US Food and Drug Administration advisory committee recommendations for the COX-2 inhibitor drugs are likely to lead to
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
4 April 2005
24 May 2013
© 2013 thepharmaletter.com